BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 23408436)

  • 1. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
    Schepis F; Vukotic R; Berzigotti A; Carrión JA; Forns X; Abraldes JG; García-Valdecasas JC; Navasa M; García-Pagán JC; Bosch J
    Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
    Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
    Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
    La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
    J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.
    Villanueva C; Albillos A; Genescà J; Abraldes JG; Calleja JL; Aracil C; Bañares R; Morillas R; Poca M; Peñas B; Augustin S; Garcia-Pagan JC; Pavel O; Bosch J
    Hepatology; 2016 Jan; 63(1):197-206. PubMed ID: 26422126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carvedilol or propranolol in portal hypertension? A randomized comparison.
    Hobolth L; Møller S; Grønbæk H; Roelsgaard K; Bendtsen F; Feldager Hansen E
    Scand J Gastroenterol; 2012 Apr; 47(4):467-74. PubMed ID: 22401315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P; Samonakis D; Cholongitas E; Patch D; O'Beirne J; Dhillon AP; Rolles K; McCormick A; Hayes P; Burroughs AK
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
    Agasti AK; Mahajan AU; Phadke AY; Nathani PJ; Sawant P
    J Dig Dis; 2013 May; 14(5):266-71. PubMed ID: 23280243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.
    Gupta N; Kumar A; Sharma P; Garg V; Sharma BC; Sarin SK
    Liver Int; 2013 Sep; 33(8):1148-57. PubMed ID: 23601333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Propranolol and 5-isosorbide mononitrate in patients with cirrhosis: systemic and portal hemodynamic events].
    Castaño G; Viudez P; Sookoian S; Carlevaro O; Riccitelli M; Frider B
    Gastroenterol Hepatol; 2000; 23(6):275-81. PubMed ID: 15324622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients.
    Sharma P; Kumar A; Jha S; Mishra SR; Sharma BC; Sarin SK
    Aliment Pharmacol Ther; 2010 Jul; 32(1):105-12. PubMed ID: 20345511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria.
    Merkel C; Bolognesi M; Berzigotti A; Amodio P; Cavasin L; Casarotto IM; Zoli M; Gatta A
    J Hepatol; 2010 Jan; 52(1):45-53. PubMed ID: 19914730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
    Bishnu S; Ahammed SM; Sarkar A; Hembram J; Chatterjee S; Das K; Dhali GK; Chowdhury A; Das K
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):54-59. PubMed ID: 29099421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis.
    Samonakis DN; Cholongitas E; Thalheimer U; Kalambokis G; Quaglia A; Triantos CK; Mela M; Manousou P; Senzolo M; Dhillon AP; Patch D; Burroughs AK
    Liver Transpl; 2007 Sep; 13(9):1305-11. PubMed ID: 17763383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance in patients with cirrhosis and portal hypertension.
    Erice E; Llop E; Berzigotti A; Abraldes JG; Conget I; Seijo S; Reverter E; Albillos A; Bosch J; García-Pagán JC
    Am J Physiol Gastrointest Liver Physiol; 2012 Jun; 302(12):G1458-65. PubMed ID: 22492691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study.
    La Mura V; Abraldes JG; Berzigotti A; Erice E; Flores-Arroyo A; García-Pagán JC; Bosch J
    Hepatology; 2010 Jun; 51(6):2108-16. PubMed ID: 20512998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol.
    Aramaki T; Sekiyama T; Katsuta Y; Kurokawa H; Komeichi H; Tsutsui H; Terada H; Ohsuga M; Satomura K; Okumura H
    J Hepatol; 1992 May; 15(1-2):48-53. PubMed ID: 1354676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis.
    Bandi JC; García-Pagán JC; Escorsell A; François E; Moitinho E; Rodés J; Bosch J
    Hepatology; 1998 Sep; 28(3):677-82. PubMed ID: 9731558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new beta-blocker with nitrovasodilating properties in patients with liver cirrhosis.
    Sugano S; Kawafune T; Suzuki T; Kubota M; Okajima T; Sumino Y; Akita H
    Am J Gastroenterol; 1995 May; 90(5):788-93. PubMed ID: 7733089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.